Oncotarget | Plasma Growth Hormone a Potential Biomarker of Response to Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma Patients
December 22, 2022
In conclusion, our study demonstrate[s] that plasma GH represents a candidate biomarker for predicting treatment outcomes in patients with advanced HCC treated with Atezo/Bev.”—BUFFALO, NY- December 22,... read more